SCHEMBL3389752

SCHEMBL3389752

CCCCCCC(CCCO)CCCCCC

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.68
ALDH1A1 P00352 3/20 0.60
HSD17B10 Q99714 1/20 0.60
MEN1 O00255 1/20 0.60
KMT2A Q03164 1/20 0.60
TSHR P16473 1/20 0.60
SMN1; SMN2 Q16637 1/20 0.55
PTPN1 P18031 1/20 0.46
CYP2D6 P10635 2/20 0.45
SPHK1 Q9NYA1 2/20 0.45
GMNN O75496 1/20 0.45
POLB P06746 1/20 0.45
THPO P40225 1/20 0.45
MTOR P42345 1/20 0.45
BLM P54132 1/20 0.45
KDM4E B2RXH2 1/20 0.45
TP53 P04637 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
MAPT P10636 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9438396 1.00 LMNA (0.68) LMNAALDH1A1HSD17B10MEN1KMT2A
SCHEMBL9438313 1.00 LMNA (0.68) LMNAALDH1A1HSD17B10MEN1KMT2A
SCHEMBL9438215 1.00 LMNA (0.68) LMNAALDH1A1HSD17B10MEN1KMT2A
SCHEMBL11675408 1.00 LMNA (0.68) LMNAALDH1A1HSD17B10MEN1KMT2A
SCHEMBL9438222 1.00 LMNA (0.68) LMNAALDH1A1HSD17B10MEN1KMT2A
SCHEMBL20943375 1.00 LMNA (0.68) LMNAALDH1A1HSD17B10MEN1KMT2A
SCHEMBL15478664 1.00 LMNA (0.68) LMNAALDH1A1HSD17B10MEN1KMT2A
SCHEMBL15478680 1.00 LMNA (0.68) LMNAALDH1A1HSD17B10MEN1KMT2A
SCHEMBL20943378 1.00 LMNA (0.68) LMNAALDH1A1HSD17B10MEN1KMT2A
SCHEMBL9644075 1.00 LMNA (0.68) LMNAALDH1A1HSD17B10MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3478277-B1 ANTI-ACNE COMPOSITIONS AND METHODS OF USE OREAL (FR) 2021-06-23 EP claimed
EP-2640345-B1 IMPROVEMENT OF THE APPEARANCE OF FACIAL PORES PROCTER & GAMBLE (US) 2018-03-28 EP claimed
EP-2640347-B1 IMPROVEMENT OF THE APPEARANCE OF FINE LINES AND WRINKLES PROCTER & GAMBLE (US) 2018-03-21 EP claimed
EP-1834628-B1 Cosmetic composition comprising phytosterols, isoflavones and methylricinoleate, use as inhibitor of 5-alpha-reductase and hair growth FIRST S P A (IT) 2010-12-29 EP claimed
EP-0521562-B1 Vesicles in non-polar media YAMANOUCHI EUROP BV (NL) 2003-03-05 EP claimed
CN-119505367-A Diisooctyl terephthalate/isononyl/isodecyl ester plasticizer composition, and preparation method and application thereof 珠海市拾月新材料有限公司 2025-02-25 CN disclosed
CN-119431888-A Isooctyl pyromellitate/isononyl isodecyl ester plasticizer composition, and preparation method and application thereof 珠海市拾月新材料有限公司 2025-02-14 CN disclosed
US-20250049948-A1 NOVEL IONIZABLE LIPIDS AND LIPID NANOPARTICLES AND METHODS OF USING THE SAME SAIL BIOMEDICINES, INC. 2025-02-13 US disclosed
CN-118829625-A Novel ionizable lipids and lipid nanoparticles and methods of use thereof 赛欧生物医药股份有限公司 2024-10-22 CN disclosed
EP-4433450-A1 NOVEL IONIZABLE LIPIDS AND LIPID NANOPARTICLES AND METHODS OF USING THE SAME Sail Biomedicines, Inc. (US) 2024-09-25 EP disclosed
WO-2023091490-A1 NOVEL IONIZABLE LIPIDS AND LIPID NANOPARTICLES AND METHODS OF USING THE SAME SENDA BIOSCIENCES, INC. (US) 2023-05-25 WO disclosed
US-20170267685-A1 HETEROARYL COMPOUNDS AND USES THEREOF BRISTOL-MYERS SQUIBB COMPANY 2017-09-21 US disclosed
EP-0521562-B1 Vesicles in non-polar media YAMANOUCHI EUROP BV (NL) 2003-03-05 EP disclosed
EP-1092422-B1 Composition, particularly for cosmetics containing a sapogenin OREAL (FR) 2002-06-26 EP disclosed
WO-2002002498-A1 METHOD FOR PRODUCING A NON-FATTY SOFTENER BASED ON WAX-ESTERS SOPHIM (FR) 2002-01-10 WO disclosed
EP-1092422-A1 Composition, particularly for cosmetics containing a sapogenin L'OREAL (FR) 2001-04-18 EP disclosed
EP-1050296-A1 Composition containing at least a bicyclic aromatic compound and at least a lipopholic sunscreen, and its uses L'OREAL (FR) 2000-11-08 EP disclosed
EP-1018540-A1 Process for preparing a non-fat emollient from olive extracts Sophim (FR) 2000-07-12 EP disclosed
EP-0521562-A1 Vesicles in non-polar media YAMANOUCHI EUROPE B.V. (NL) 1993-01-07 EP disclosed
WO-1993000069-A1 VESICLES IN NON-POLAR MEDIA BROCADES PHARMA B.V. (NL) 1993-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170267685-A1 HETEROARYL COMPOUNDS AND USES THEREOF PRKACA, PRKDC, AURKC LMNA 3640/4885ALDH1A1 3719/4885HSD17B10 2993/4885
US-20250049948-A1 NOVEL IONIZABLE LIPIDS AND LIPID NANOPARTICLES AND METHODS OF USING THE SAME NPC1L1, ABCB4, LIPA LMNA 1745/4885ALDH1A1 4108/4885HSD17B10 1780/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.